Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004893 · ClinicalTrials.gov registry record · Phase 2
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 20
- Study locations
NCT00004893 is a Phase 2 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 5 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00004893, a Phase 2 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of interleukin-12 in treating patients who have metastatic or recurrent breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interleukin-12
Study Locations (20)
California
- University of California San Diego Cancer Center - La Jolla
- UCSF Cancer Center and Cancer Research Institute - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
Illinois
- University of Illinois at Chicago Health Sciences Center - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
District of Columbia
- Lombardi Cancer Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Minnesota
- Veterans Affairs Medical Center - Minneapolis - Minneapolis
- University of Minnesota Cancer Center - Minneapolis
Missouri
- Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
- Ellis Fischel Cancer Center - Columbia - Columbia
Alabama
- Veterans Affairs Medical Center - Birmingham - Birmingham
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1999-12 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004893
The ClinicalTrials.gov registry entry for NCT00004893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which recombinant interleukin-12 is the first listed.
NCT00004893 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00004893 about?
NCT00004893 is a clinical study titled "Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer". RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of interleukin-12 in treating patients who have metastatic or recurrent breas...
What is the current status of trial NCT00004893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 1999-12. Estimated completion is 2002-02.
What conditions does trial NCT00004893 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00004893?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004893?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004893 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.